Lag-3 combination therapy for the treatment of cancer

A method of treating gastric cancer or gastroesophageal junction cancer in a human patient, the method comprising administering to the patient an effective amount of:

• (a) an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5,
• (b) an anti-PD-1 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:15, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:17, and
• (c) one or more chemotherapeutic agents.

A method of treating recurrent, locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma in a human patient, the method comprising:

• (a) administering to the patient an effective amount of an anti-LAG-3 antibody comprising CDR1, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDR1, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5, and
• (b) administering to the patient one or more standard-of-care therapeutic regimen.